Mayo Clinic Proceedings Home
MCP Digital Health Home

Gene Therapy for Atherosclerotic Cardiovascular Disease: A Time for Optimism and Caution

      Cardiovascular disease is the leading cause of death in the Western world, and gene therapy approaches to several cardiovascular disorders have been proposed. One of the major stumbling blocks to be overcome before widespread clinical use of this technology is how to deliver DNA efficiently and safely to cells in vivo. While delivery of DNA alone is inefficient, use of viral vectors may overcome this problem. Adenoviral vectors are most commonly used in cardiovascular gene delivery, but toxicity related to these vectors remains a concern. In addition, duration of gene expression with use of these vectors is limited, which may be advantageous in settings in which transient expression is satisfactory to obtain a therapeutic effect. Gene therapy has been suggested as an approach to multiple conditions, including restenosis after angioplasty, therapeutic neovascularization, and bypass graft restenosis. Phase 1 clinical trials were recently reported. While proof of principle has been established in preclinical animal models, convincing efficacy data in humans do not yet exist. Improvements in vector technology and methods of catheter . mediated vascular gene delivery are needed before widespread clinical application of this therapy.
      LDL (low-density lipoprotein), VEGF (vascular endothelial growth factor)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pickering JC
        • Takcshita S
        • Feldman L
        • Losordo DW
        • Isncr JM
        Vascular applications of human gene therapy.
        Semin Interr Cardiol. 1996; 1: 84-88
        • Schneider MD
        • French BA
        The advent of adenovirus: gene therapy for cardiovascular disease.
        Circulation. 1993; 88: 1937-1942
        • Bergelson JM
        • Cunningham JA
        • Drogue G
        • et al.
        Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.
        Seience. 1997; 275: 1320-1323
        • Kochanek S
        High-capacity adenoviral vectors for gene transfer and somatic gene therapy.
        Hum Gene Ther. 1999; 10: 2451-2459
        • Svensson EC
        • Marshall DJ
        • Woodard K
        • et al.
        Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors.
        Circulation. 1999; 99: 201-205
        • Amado RG
        • Chen IS
        Lcnliviral vectors—the promise of gene therapy within reach?.
        Science. 1999; 285: 674-676
        • Vile RG
        • Tuszynski A
        • Castleden S
        Retroviral vectors: from laboratory tools lo molecular medicine.
        Mol Biotechnol. 1996; 5: 139-158
        • O'Brien T
        Gene therapy and inherited dyslipidcmia.
        Endocr Pract. 1996; 2: 37-43
        • Phillips MI
        Is gene therapy for hypertension possible? [editorial].
        Hypertension. 1999; 33: 8-13
        • Giannoukakis N
        • Rudert WA
        • Robbins PD
        • Trucco M
        Targeting autoimmune diabetes with gene therapy.
        Diabetes. 1999; 48: 2107-2121
        • De Young MB
        • Dichek DA
        Gene therapy for restenosis: are we ready?.
        Cite Res. 1998; 82: 306-313
        • Libby P
        Gene therapy of restenosis: promise and perils [editorial).
        CircRes. 1998; 82: 404-406
        • Simari RD
        • San H
        • Rekhter M
        • et al.
        Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries.
        J Clin Invest. 1996; 98: 225-235
        • Mehta D
        • Izzat MB
        • Bryan AJ
        • Angelini GD
        Towards the prevention of vein graft failure.
        Int J Cardiol. 1997; 62: S55-S63
        • Cable DG
        • Caccitolo JA
        • Caplice N
        • et al.
        The role of gene therapy for intimai hyperplasia of bypass grafts.
        Circulation. 1999; 100: II-392-II-396
        • Losordo DW
        • Vale PR
        • isner JM
        Gene therapy for myocardial angiogenesis.
        Am Heart j. 1999; 138: 132-141
        • Chen AFY
        • O'Brien T
        • Katusic ZS
        Transfer and expression of recombinant nitric oxide synthase genes in the cardiovascular system.
        Trends Pharmacol Sei. 1998; 19: 276-286
        • Grossman M
        • Rader DJ
        • Müller DW
        • et al.
        A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.
        Nat Med. 1995; 1: 1148-1154
        • Hobbs HH
        • Brown MS
        • Goldstein JL
        Molecular genetics of the LDL receptor gene in familial hypercholestcrolemia.
        Hum Mutai. 1992; 1: 445-466
        • Brown MS
        • Goldstein JL
        • Havel RJ
        • Steinberg D
        Gene therapy for cholesterol [letter].
        Nat Genet. 1994; 7: 349-350
        • Schumacher B
        • Pecher P
        • von Specht BU
        • Stegmann T
        Induction of neoangiogencsis in ischémic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease.
        Circulation. 1998; 97: 645-650
        • Laham RJ
        • Sellke FW
        • Edelman ER
        • et al.
        Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial.
        Circulation. 1999; 100: 1865-1871
        • Rosengart TK
        • Lee LY
        • Patel SR
        • et al.
        Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
        Circulation. 1999; 100: 468-474
        • Losordo DW
        • Vale PR
        • Symes JF
        • et al.
        Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.
        Circulation. 1998; 98: 2800-2804
        • Isner JM
        • Pieczck A
        • Schainfeld R
        • et al.
        Clinical evidence of angiogenesis after arterial gene transfer of phVEGF 165 in patient with ischaemic limb.
        Ijmcet. 1996; 348: 370-374
        • Baumgartner I
        • Pieczek A
        • Manor O
        • et al.
        Constitutive expression of phVEGF 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.
        Circulation. 1998; 97: 1114-1123